NfL Biomarker Findings for hATTR Amyloidosis with Polyneuropathy Presented at ANA 2022

NfL Biomarker Findings for hATTR Amyloidosis with Polyneuropathy Presented at ANA 2022

New 18-month findings evaluating Neurofilament light chain (NfL) as a potential biomarker of treatment response in patients with hATTR amyloidosis with polyneuropathy were presented at the 147th annual meeting of the American Neurological Association (ANA).

Aldinc, et al. “NfL Levels Significantly Decrease in Response to Treatment with Patisiran or Vutrisiran in hATTR Amyloidosis with Polyneuropathy”



SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.